阿司咪唑上市后心血管系统安全性评价

阿司咪唑(第2代抗过敏药)因其不良反应逐渐引起了人们的关注,特别是潜在心脏方面的毒性。在现有的国外文献中,对于阿司咪唑的心脏毒性持有争议。有学者认为,阿司咪唑在心脏方面毒性反应罕见且危险性较小;也有学者认为,阿司咪唑在心脏方面毒性可致命且危险性高。阿司咪唑的心脏毒性表现为尖端扭转型室性心动过速、室性心动过速、房室传导阻滞和QT间期延长。临床心脏毒性的发生与阿司咪唑剂量过大或合用CYP3A4抑制剂密切相关。

Safety assessment of astemizole in cardiovascular system of post marketed

Astemizole is a kind of second-generation antihistamines, but its cardiotoxicity is attracting increasing attention.There are still some dispute about the cardiotoxicity of astemizole in foreign literatures. The cardiotoxicity of astemizole have been associated with torsades de pointes,ventricular arrthythmia,atrioventricular blockage,and prolonga- tion of the QT interval when over-dosage or taking CYP3A4 inhibitor together.